Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00095394 · ClinicalTrials.gov registry record · Phase 3
Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 645
- Enrollment target
NCT00095394 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 645 participants.
The verdict
NCT00095394, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 645 participants
- Enrollment target
Study Summary
The purpose of this clinical research is to learn if severe hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate the safety and tolerability of the drugs.
Interventions
- DRUG Irbesartan/HCTZ
- DRUG Irbesartan monotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 645 participants |
| Start Date | 2004-09 |
| Est. Completion | 2005-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00095394
The ClinicalTrials.gov registry entry for NCT00095394 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 645 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Irbesartan/HCTZ is the first listed.
NCT00095394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00095394 about?
NCT00095394 is a clinical study titled "Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension". The purpose of this clinical research is to learn if severe hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate th...
What is the current status of trial NCT00095394?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 645 participants. The study started on 2004-09. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00095394?
The interventions under investigation include: Irbesartan/HCTZ (DRUG), Irbesartan monotherapy (DRUG).
Who is sponsoring clinical trial NCT00095394?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.